0.32 USD
▲-0.03+2.09%
盘后 0.32 +0.41%
2026-08-03
市值
$51.41M
市盈率
—
EPS
-0.22
股息率
—
52 周区间
0.20 – 2.37
成交量
361.28K
Beta
0.29
目标价
1.98
52W 低 0.2052W 高 2.37
价格走势
公司简介
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an o...